Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.62 |
| ▸ | CA2 | P00918 | 13/20 | 0.62 |
| ▸ | CA9 | Q16790 | 13/20 | 0.62 |
| ▸ | IKBKB | O14920 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11274499 | 0.83 | CA2 (0.59) | CA1CA2CA9IKBKBCA12 | |
| SCHEMBL1633099 | 0.81 | IKBKB (0.65) | CA1CA2CA9IKBKBCA12 | |
| SCHEMBL28747203 | 0.80 | CA1 (0.67) | CA1CA2CA9IKBKBCA12 | |
| SCHEMBL24477607 | 0.79 | CA2 (0.59) | CA1CA2CA9IKBKBCA12 | |
| SCHEMBL24477734 | 0.79 | CDK2 (0.60) | CA1CA2CA9IKBKBCA12 | |
| SCHEMBL27587969 | 0.79 | CA2 (0.58) | CA1CA2CA9CA12CA14 | |
| SCHEMBL24477605 | 0.78 | LRRK2 (0.60) | CA1CA2CA9IKBKBCA12 | |
| SCHEMBL5259079 | 0.78 | AURKA (0.59) | CA1CA2CA9IKBKBCA12 | |
| Sulfameter SCHEMBL28250749 | 0.77 | LMNA (0.89) | CA1CA2CA9CA12CA14 | |
| SCHEMBL1652316 | 0.77 | IKBKB (0.64) | CA1CA2CA9IKBKBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113755911-A | Cyanide-free silver-plated anti-tarnish agent and application thereof | 重庆立道新材料科技有限公司 | 2021-12-07 | — | — | CN | claimed |
| EP-0255100-A2 | Use of trimetrexate and its salts for the preparation of pharmaceutical compositions for treating infections of the mycobacterium-avium-intracellulare complex | WARNER-LAMBERT COMPANY (US) | 1988-02-03 | — | — | EP | claimed |
| CN-113755911-A | Cyanide-free silver-plated anti-tarnish agent and application thereof | 重庆立道新材料科技有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7553971-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1446379-B1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
| US-7125892-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060178410-A1 | Preparation of N-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-2-hydroxy-2-(3-hydroxymethyl-4-hydroxyphenyl)ethylamine, for example; for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-08-10 | — | — | US | disclosed |
| EP-1641465-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005025555-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1446379-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040063755-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-04-01 | — | — | US | disclosed |
| US-6670376-B1 | Asthma or chronic obstructive pulmonary disease; pre-term labor, neurological and cardiac disorders, inflammation; N-(2-(4-(3-phenyl-4-methoxyphenyl) aminophenyl)ethyl)-(R)-2-hydroxy-2-(3- hydroxymethyl-4-hydroxyphenyl)ethylamine | THERAVANCE, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-12-11 | — | — | US | disclosed |
| WO-2003042164-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-0255100-A2 | Use of trimetrexate and its salts for the preparation of pharmaceutical compositions for treating infections of the mycobacterium-avium-intracellulare complex | WARNER-LAMBERT COMPANY (US) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | CA1 4880/4885CA2 3005/4885CA9 4621/4885 |
| US-20040063755-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | CA1 4880/4885CA2 3687/4885CA9 4640/4885 |
| US-20060178410-A1 | Preparation of N-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-2-hydroxy-2-(3-hydroxymethyl-4-hydroxyphenyl)ethylamine, for example; for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease | ADRB2, ADRB3, ADRA2C | CA1 4880/4885CA2 3475/4885CA9 4776/4885 |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | CA1 4877/4885CA2 3305/4885CA9 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.